COVID19 and human reproduction joint statement
Thursday, June 04, 2020
Several of the world’s peak reproduction groups, the American Society of Reproductive Medicine, the European Society of Human Reproduction and embryology and the International Federation of Fertility Societies have issued a joint statement about coronavirus and human reproduction:
The American Society of Reproductive Medicine, the European Society of Human Reproduction and Embryology, and the International Federation of Fertility Societies have affirmed in a joint statement that reproduction is an essential human right that transcends race, gender, sexual orientation, and country of origin; a human right to which the COVID-19 pandemic has posed unique threats and challenges. Reproductive health care professionals are in a special position to provide advocacy for this right and promote the health and well-being of their patients.
Declaration of principle
Reproduction is an essential human right that transcends race, gender, sexual orientation, or country of origin. Infertility is the impairment of reproductive capacity; it is a serious disease that affects 8-12% of couples of reproductive age and harms physical and mental well-being. Infertility is time-sensitive, and prognosis worsens with age. While there is no cure for most causes, the disease is most often treatable, and the majority of patients who seek treatment can ultimately become parents.
Defining the problem
The COVID-19 pandemic presents a unique global challenge on a scale not previously seen. The infectivity and mortality rates are higher than previous pandemics and the disease is present in almost every country. The propagation and containment have varied widely by location and, at present, the timeline to complete resolution is unknown. In the earliest stages of the pandemic, the American Society for Reproductive Medicine (ASRM) and the European Society of Human Reproduction and Embryology (ESHRE), independently recommended discontinuation of reproductive care except for the most urgent cases. More recently, with successful mitigation strategies in some areas and emergence of additional data, the societies have sanctioned gradual and judicious resumption of delivery of full reproductive care. In this document, ASRM, ESHRE and the International Federation of Fertility Societies (IFFS) have come together to jointly affirm the importance for continued reproductive care during the COVID-19 pandemic.
Reproductive medicine is essential
Reproductive care is essential for the well-being of society and for sustaining birth rates at a time that many nations are experiencing declines. During the pandemic, reproductive medicine professionals should continue to:
- Advocate for the well-being of patients.
- Monitor local conditions, including prevalence of disease, status of government or state regulations, and availability of resources.
- Implement proactive risk assessment within their practices prior to restarting services.
- Prioritize care and judiciously allocate use of limited resources using medical criteria.
- Counsel patients about all options, including deferring evaluation and treatment.
- Adhere to active risk mitigation strategies to reduce the risk of viral transmission.
- Develop clear and codified plans to ensure the ability to provide care while maximizing the safety of their patients and staff.
- Remain informed and stay current regarding new medical findings.
- Develop or refine robust emergency plans.
- Be prepared to interrupt medical treatment if conditions warrant discontinuation.
Research needed
In addition to helping patients, reproductive medicine practices are uniquely positioned to gather data and help to further COVID-19 research.
- Reproductive medicine professionals and practices are essential front-line resources for screening, monitoring, and assessing the prevalence and impact of the disease on patients and their progeny through Point-of-Care data collection.
- ESHRE, ASRM and IFFS are committed to continuous monitoring of the effects of COVID-19 on gametes and reproductive tissues, collecting data on pregnant patients infected during the pandemic, and assessing the outcomes of mothers and neonates.
- Examples of these research and registry efforts follow:
- In the U.S.A., the ASPIRE (Assessing the Safety of Pregnancy In the Coronavirus Pandemic) Study is a nationwide prospective cohort study of pregnant women and their offspring during the COVID-19 pandemic. All patients under the care of a reproductive medicine specialist who conceived spontaneously or with assisted reproductive technology (ART) between March 1st and December 31st are encouraged to participate.
- ESHRE is gathering global case-by-case reporting on the outcome of medically assisted reproduction (MAR) conceived pregnancies in women with a confirmed infection (https://nl.surveymonkey.com/r/COVID19ART).
- The affiliate society of ASRM, the Society for Assisted Reproductive Technologies (SART) is including mandatory COVID-19-related questions in their Clinic Outcome Reporting System (CORS) registry of assisted reproductive technologies (ART), which accounts for over 95% of all ART cycles in the U.S.A.
- ESHRE is gathering data and mapping MAR/ART activity during the pandemic, country by country whether and /or when they stopped offering treatment and when they have resumed care.
- IFFS is conducting COVID-19-related periodic surveys to assess global trends in access to MAR/ART services.
Final thoughts
Reproductive care is essential and reproductive medicine professionals are in a unique position to promote health and wellbeing. In addition, ASRM, ESHRE and IFFS are collaborating to advocate for patients and to gather data and resources to enhance the understanding of COVID-19 as it pertains to reproduction, pregnancy, and the impact on the fetus and neonate. The lessons learned from these experiences will be useful as humanity deals with future pandemics.
Representatives:
Anna Veiga – ESHRE/Spain
Luca Gianaroli – ESHRE/Italy
Steve Ory – IFFS/USA
Marcos Horton – IFFS/Argentina
Eve Feinberg – ASRM/USA
Alan Penzias – ASRM/USA
